Sanofi (NASDAQ:SNY) and GlaxoSmithKline (NYSE:GSK) ink a letter of intent to co-develop an adjuvanted vaccine for COVID-19.
Sanofi will contribute its recombinant RNA-based S-protein COVID-19 antigen, while GSK will contribute its adjuvant technology.
A Phase 1 study should launch in H2. If development goes well, the vaccine could be available in H2 2021.
https://seekingalpha.com/news/3560400-sanofi-and-gsk-team-up-to-develop-covidminus-19-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.